SMARTER SOLUTIONS

Prioritizing a Medical Necessity

In a perfect world, clinicians and labs would be able to guarantee accurate medication management with zero adverse drug interactions for patients. Until then, there’s PGxPopulation, our dynamic solution for determining which populations would benefit the most from pharmacogenomics testing.

Learn more about pharmacogenomics
EFFICIENT SOLUTIONS

Pinpoint the Best Patients for Testing

Precision Medicine at Population Scale
LOWER RISK

Precision Medicine at Population Scale

Rather than testing everyone, PGxPopulation enables laboratories, independent software vendors, and healthcare providers to save time and money by looking at a cohort and seeing which populations should participate in pharmacogenomics testing.

Optimize Your Resources
BETTER OUTCOMES

Optimize Your Resources

For population health programs, knowing how to allocate resources and when to screen patients can increase the quality of care and services delivered. Translational Software’s PGxPopulation identifies the gene-specific reasons that a pharmacogenomics test may be beneficial, helping reduce the risk of adverse events and lowering healthcare costs.

Identify Ideal Populations
SMARTER MEDICINE

Identify Ideal Populations

Preventative screening programs are more effective when providers are focused on patients who need PGx testing the most. Some  relevant populations include:

  • Long-term care patients: Evaluate your patient population periodically to ensure they’re receiving the appropriate clinical therapy to reduce adverse drug reactions.
  • Transitional care patients: Properly review gene-medication interactions to prevent readmissions for older adults when entering post-acute care.
  • Employee benefits: Improve metrics around absenteeism and increase overall productivity by ensuring the appropriateness of medication therapies for your workforce.
POPULATION REPORTING

How Does It Work?

Nullam quis risus eget urna mollis ornare vel eu leo. Praesent commodo cursus magna, vel scelerisque nisl consectetur et. Aenean eu leo quam pellentesque ornar.
POPULATION REPORTING

How Does It Work?

The healthcare provider collects de-identified data for a specific population, such as an organization’s workforce, and uploads it into PGxPopulation. Then, Translational Software will analyze the data and deliver an aggregate report for the population.

The PGxPopulation report will display whether a pharmacogenomics test is required by the FDA, is strongly recommended, is recommended, may be beneficial, or has limited benefits for the tested population. Additionally, within each individual patient record, you can view the following:

  • Patient's current prescriptions
  • Risk of drug interactions
  • Relevant gene
  • Adverse interaction that can occur
  • Prevalence of the interaction
  • Guidance based on our heavily vetted knowledge base
TESTIMONIALS

What People Say

  • "Translational Software has taken the pioneering step of implementing the first pharmacogenomics solution that employs FHIR genomics for optimizing the prescription of patient medications, and has been a real leader in this arena."
    GIL ALTEROVITZ, PHD

    GIL ALTEROVITZ, PHD

    Gil Alterovitz, Ph.D., a Harvard Medical School professor and co-chair of HL7’s Clinical Genomics Work Group

  • "Integrating Translational Software’s PGx knowledge base within our e-prescribing platform allows us to deliver an in-workflow, evidence-based approach to medication prescribing that can be used as part of routine care."
    G. CAMERON DEEMER

    G. CAMERON DEEMER

    President of DrFirst